Gene aberrations in APM, including loss of 20S proteasome subunits and tumor-intrinsic loss of MHC-I, as well as mutations in IFNγ response pathway genes have been reported as hallmarks of PD-1 or PD-L1 ICB resistance due to loss of tumor immune recognition [14–17]. The gene discussed is PDCD1; the disease is neoplasm.